SPY396.92+7.29 1.87%
DIA318.84+6.42 2.05%
IXIC11,535.28+180.66 1.59%

Tarsus Pharmaceuticals Says Phase 3 Trial of TP-03 to Treat Eyelid Disease Meets Primary, Secondary Endpoints

MT Newswires · 05/02/2022 04:30

Please log in to view news